[CAS NO. 2376580-08-2] SU056
PRODUCTS SPECIFICATIONS [2376580-08-2]
DESCRIPTION [2376580-08-2]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 369.34 |
| Molecular Formula | C20H16FNO5 |
| SMILES | O=C1OCC2=C1C(C3=CC4=C(C=C3N2CCO)OCO4)C5=CC(F)=CC=C5 |
Summary
IC50 & Target
YB-1 [1]
In Vitro
SU056 (0-10 μM approximately, 48 h) inhibits cell growth in OVCAR3/4/5/8, SKOV3 and ID8 cells
[1]
。
SU056 (1 μM, 5-8 days) inhibits colony formation in a dose-dependent manner in OVCAR-8 and ID8 cells
[1]
。
SU056 (1-5 μM, 6 h) arrests OVCAR8, SKOV3, and ID8 cells in the sub-G1 and G1 phases
[1]
.
SU056 (0-1 μM, 12 h) inhibits cell migration in OVCAR8, SKOV3, and ID8 cells
[1]
.
SU056 (0-5 μM, 24 h) induces apoptotic cell death in OVCAR8, SKOV3, and ID8 cells
[1]
.
SU056 (1-5 μM, 12 h) inhibited the expression of YB-1, TMSB10, SUMO2, and PMSB2 proteins in OVCAR8 cells
[1]
.
SU056 (0.1, 0.5, and 1 μM, 48 h) enhances the cytotoxic effects of Paclitaxel (HY-B0015) (0.1, 0.5, and 1 nM)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | OVCAR3/4/5/8, SKOV3 and ID8 cells |
| Concentration: | 0-10 μM approximately |
| Incubation Time: | 48 h |
| Result: | Inhibited cell growth with IC 50 values of 1.27, 6.8, 4.33, 3.18, 1.73, 3.75 μM. |
Cell Migration Assay [1]
| Cell Line: | OVCAR8, SKOV3, and ID8 cells |
| Concentration: | 0, 0.5, 1 μM |
| Incubation Time: | 12 h |
| Result: | Dose-dependently inhibited cell migration. |
Western Blot Analysis [1]
| Cell Line: | OVCAR8 cell |
| Concentration: | 1-5 μM |
| Incubation Time: | 12 h |
| Result: | Dose-dependently inhibited the YB-1, TMSB10, SUMO2, and PMSB2 proteins. |
In Vivo
SU056 (20 mg/kg, i.p.) inhibits tumor growth in mice implanted with ID8 cells
[1]
.
SU056 (10 mg/kg, i.p., daily) combined with Paclitaxel (HY-B0015) (5 mg/kg, weekly, i.p.) shows a much greater reduction in OC tumor growth in immunodeficiency mice implanted with OVCAR8 OC tumors
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 mice implanted (s.c.) with luciferase-expressing ID8 cells [1] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: |
Reduced the tumor weight by 2-fold, and is well-tolerated.
Reduced the lung metastases. Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample). |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.